Why Long-Term Aspirin is Preferred Over Oral Anticoagulation After PFO Closure
After PFO closure, long-term antiplatelet therapy (aspirin) is preferred over oral anticoagulation because the device itself eliminates the paradoxical embolism pathway, making anticoagulation unnecessary and exposing patients to higher bleeding risks without additional stroke prevention benefit.
The Fundamental Rationale
The key to understanding this preference lies in recognizing what PFO closure accomplishes mechanistically. Once the PFO is successfully closed with a device, the anatomical conduit for paradoxical embolism is eliminated 1, 2. The primary stroke mechanism—venous clots crossing from right to left atrium through the PFO—is physically blocked. This fundamentally changes the risk-benefit calculation for antithrombotic therapy.
Evidence-Based Recommendations
Post-Closure Antiplatelet Protocol
The standard approach after PFO closure follows a stepwise de-escalation 1, 3:
- First 3 months: Dual antiplatelet therapy (aspirin 75 mg/day + clopidogrel 75 mg/day) to prevent device-related thrombus formation during endothelialization 3, 4
- After 3 months to ≥5 years: Single antiplatelet therapy (aspirin or clopidogrel) 1, 3
- Beyond 5 years: Decision based on individual stroke and bleeding risk 4
This protocol addresses the temporary thrombogenic risk of the closure device itself while it becomes endothelialized, not the original PFO-related stroke mechanism 4.
Why Not Anticoagulation?
Multiple guidelines consistently recommend against routine anticoagulation after PFO closure 5, 1, 6:
No proven superiority: The PICSS substudy of WARSS found no significant difference between warfarin and aspirin in PFO patients (HR 0.52,95% CI 0.16-1.67, P=0.28) 7. This was before closure, when the PFO was still patent—anticoagulation showed no advantage even with an open conduit.
Higher bleeding risk: Anticoagulation carries a significantly higher major bleeding risk compared to antiplatelet therapy (risk difference +12 per 1000 patients over 5 years) 8. After closure eliminates the paradoxical embolism pathway, this bleeding risk becomes unjustifiable.
Mechanism-specific treatment: Anticoagulation is indicated when there's ongoing risk of cardiac thrombus formation (atrial fibrillation, left ventricular thrombus, hypercoagulable states) 5, 6. The closed PFO device doesn't create such risk once endothelialized—it simply requires temporary antiplatelet coverage during healing.
Clinical Decision Algorithm
Anticoagulation after PFO closure is only indicated when there's a separate, independent indication 1, 6:
- Atrial fibrillation (especially post-closure AF, which occurs in ~5% of patients) 1, 2
- Documented hypercoagulable state with venous thromboembolism 5, 6
- Left ventricular thrombus 1
- Other established anticoagulation indications
In the absence of these conditions, antiplatelet therapy alone is sufficient and safer 5, 1, 6, 7.
Important Caveats
The Atrial Fibrillation Complication
PFO closure probably increases the risk of persistent atrial fibrillation (risk difference +18 per 1000 patients) 8. If post-closure atrial fibrillation develops, this creates a new indication for anticoagulation based on stroke risk stratification (CHA₂DS₂-VASc score), independent of the PFO closure itself 2.
Uncertainty in Specific Populations
The evidence base has limitations:
- Patients >60 years: Insufficient evidence for PFO closure benefit; if closure is performed, the same antiplatelet approach applies 1, 2
- Patients already on anticoagulation: The decision regarding PFO closure remains unclear, and management should be individualized 1
- Direct oral anticoagulants (DOACs): No head-to-head trials comparing DOACs to aspirin after PFO closure exist 9, 10
The Bottom Line
Aspirin is preferred because it addresses the only remaining thrombotic risk (device endothelialization) while avoiding the bleeding complications of anticoagulation that would serve no additional purpose once the PFO is mechanically closed 5, 1, 6, 7. The device eliminates the stroke mechanism; antiplatelet therapy protects the device during healing. Anticoagulation would add bleeding risk without reducing stroke risk in this specific context.
This represents a mechanism-based approach: treat the device (antiplatelet), not the closed anatomical defect (which no longer requires anticoagulation) 2, 3.